Digital & Computational Pathology - Senior Director of Biomarker Sciences, Top 15 Pharma

A senior director of biomarker sciences at a top 15 pharma company discusses how they utilize and implement digital pathology. Their use of digital pathology includes pre-clinical research, as well as routinely scanning pathology slides from clinical trials for immediate or future use. This stakeholder was familiar with a wide variety of vendors in the space, mentioning Leica, Proscia, Visiopharm, Indica Labs, PathAI, Paige.AI, and OracleBio as some of the top vendors. They have a preference for selecting vendors based on individual strengths and integrating each vendor into their digital pathology workflow. They report that their spend has shifted primarily towards software and data storage costs, though they predict they will build out a new lab in the next five years and will purchase new hardware as part of that process. Their organization looks to harmonize the digital pathology workflow and will be implementing a standardized workflow, including use of vendors, across all locations. This stakeholder suggests that as the market evolves and spend shifts from hardware to software, digital pathology companies will need to adapt and innovate to find new revenue streams.

‍